Generic drug makers are responsible for providing sufficient information in their abbreviated new drug applications (ANDA) to show that the generic drug’s active ingredient is the same as that of its reference listed drug (RLD), the FDA said in a draft guidance issued today.
Source: Drug Industry Daily